Compare Eli Lilly And Co (LLY) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Consumer Staples Select Sector SPDR Fund — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Consumer Staples Select Sector SPDR Fund trades at $83.37 (market cap $13.50B). The key difference: Eli Lilly And Co is far larger — about 77× Consumer Staples Select Sector SPDR Fund's market cap, and Eli Lilly And Co pays a 0.59% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| LLY | XLP | |
|---|---|---|
Market Cap | $1.04T | $13.50B |
Volume | 3,064,878 | 14,599,953 |
Sector | Health | — |
52-Week High | $1.28K | $90.00 |
52-Week Low | $799.57 | $75.61 |
Typical Hold Time | 93 Days | 72 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
XLP trades at $83.43, up 2.12% with strong bullish technical signals from moving averages and oscillators. The ETF shows defensive sector strength, gaining 6.6% year-to-date while consumer discretionary lags. Analyst consensus is unanimously bullish with 100% buy ratings. Recent dividend declaration of $0.54 payable in September 2026 adds income appeal.
Outlook remains positive given consumer staples' defensive characteristics amid economic uncertainty. Key opportunities include sector outperformance and dividend yield, while risks center on interest rate sensitivity and potential consumer spending slowdown. The ETF's low 0.08% expense ratio provides cost advantage over peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
